Predictive validity of Lupus Patient-Reported Outcome for damage accrual in patients with systemic lupus erythematosus: the LUNA Registry

The predictive validity of disease-specific quality of life (QOL) remains unknown in patients with systemic lupus erythematosus (SLE), although disease-specific measures are equally or more responsive to changes than generic QOL. We aimed to examine the predictive validity of the Lupus patient-repor...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Rheumatology (Oxford, England) England), 2024-06
Hauptverfasser: Nose, Yoko, Onishi, Akira, Nishimura, Keisuke, Yamamoto, Yuzuru, Sada, Ken-Ei, Ichinose, Kunihiro, Yoshimi, Ryusuke, Ohno, Shigeru, Yanai, Ryo, Kajiyama, Hiroshi, Sato, Shuzo, Shimojima, Yasuhiro, Fujiwara, Michio, Kida, Takashi, Miyawaki, Yoshia, Matsuo, Yusuke, Tsuji, Hideaki, Morinobu, Akio, Saegusa, Jun
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The predictive validity of disease-specific quality of life (QOL) remains unknown in patients with systemic lupus erythematosus (SLE), although disease-specific measures are equally or more responsive to changes than generic QOL. We aimed to examine the predictive validity of the Lupus patient-reported outcome (PRO) for damage accrual. Patients with SLE and ≥2 measurements over time were included in Japanese nationwide multicentre registry (LUNA). The Lupus PRO questionnaire contains both health-related (HR) and non-HR-QOL measures. Damage accrual was evaluated using the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). We examined the association between the Lupus-PRO score at baseline and longitudinal SDI scores using mixed-effects models adjusted for prognostic factors. Among 1295 patients, those with higher HR-QOL of Lupus PRO at baseline demonstrated a significantly lower increase in SDI (-0.005/year, 95% confidence interval [CI]: -0.007 to - 0.004, p 
ISSN:1462-0324
1462-0332
1462-0332
DOI:10.1093/rheumatology/keae341